摘要
结肠直肠癌(Colorectal cancer,CRC)是消化系统常见的恶性肿瘤之一。目前治疗晚期CRC的主要手段仍是化学治疗,但由于疾病进展后化疗方案失效、毒副反应、化疗耐药等问题出现,患者总体疗效并不十分理想。近年来,随着靶向治疗的发展,化疗联合靶向治疗延长患者总体生存期、克服化疗耐药性等方面的优势突显,肿瘤的免疫治疗也在快速发展。本文将对晚期CRC患者化疗、靶向治疗及免疫治疗的相关问题进行探讨。
Objective Colorectal cancer(CRC)is one of the most common malignant tumors in the digestive system.At present,chemotherapy is still the main method for the treatment of advanced CRC,but after the progression of the disease,the failure of chemotherapy regimens,toxic and side effects,chemotherapy resistance and other problems appear,and the overall efficacy in patients is not very ideal.In recent years,with the development of targeted therapy,the advantages of chemotherapy combined with targeted therapy in prolonging the overall survival of patients and overcoming chemotherapy resistance are highlighted,and tumor immunotherapy is also developing.This article discusses the issues related to chemotherapy,targeted therapy and immunotherapy for patients with advanced CRC.
作者
张晨晨
薛宇
陈丹妮
袁喜先
ZHANG Chen-chen;XUE Yu;CHEN Dan-ni;YUAN Xi-xian(Jiamusi University,Jiamusi 154007,China;Department of Gastroenterology,The First Affiliated Hospital of Jiamusi University,Jiamusi 154003,China)
出处
《实用药物与临床》
CAS
2022年第5期453-458,共6页
Practical Pharmacy and Clinical Remedies
关键词
结直肠癌
化疗药物
分子靶向治疗
免疫治疗
Colorectal cancer
Chemotherapy drugs
Molecular targeted therapy
Immunotherapy
